Trial · NCT01759511
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Safety Profile of Simtuzumab | Simtuzumab | Adverse Events (AEs) | 97.1 | percentage of participants | |
| Overall Safety Profile of Simtuzumab | Simtuzumab | Grade 3 or 4 AEs | 47.1 | percentage of participants | |
| Overall Safety Profile of Simtuzumab | Simtuzumab | Serious Adverse Events | 35.3 | percentage of participants | |
| Overall Safety Profile of Simtuzumab | Simtuzumab | SAEs Related to simtuzumab | 5.9 | percentage of participants | |
| Overall Safety Profile of Simtuzumab | Simtuzumab | AEs leading to discontinuation of simtuzumab | 29.4 | percentage of participants | |
| Relative Change From Baseline in FVC % Predicted at Weeks 72 and 144 | Simtuzumab | Week 72 | -8.05 | Standard Error 1.829 | percent change in FVC % predicted |
| Relative Change From Baseline in FVC % Predicted at Weeks 72 and 144 | Simtuzumab | Week 144 | -12.04 | Standard Error 2.086 | percent change in FVC % predicted |
| Relative Change From Baseline in DLCO % Predicted at Weeks 72 and 144 | Simtuzumab | Week 72 | -7.41 | Standard Error 3.062 | percent change in DLCO % predicted |
| Relative Change From Baseline in DLCO % Predicted at Weeks 72 and 144 | Simtuzumab | Week 144 | -22.80 | Standard Error 3.475 | percent change in DLCO % predicted |
| All-cause Mortality | Simtuzumab | 3 | Participants | ||
| Relative Change From Baseline in Serum Lysyl Oxidase-like 2 (sLOXL2) Levels at Weeks 72 and 120 | Simtuzumab | Week 72 | 5.93 | Standard Error 5.937 | percent change in sLOXL2 |
| Relative Change From Baseline in Serum Lysyl Oxidase-like 2 (sLOXL2) Levels at Weeks 72 and 120 | Simtuzumab | Week 120 | -0.69 | Standard Error 6.032 | percent change in sLOXL2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01759511/results